A vaccine consist of a biological preparation, which upon injection stimulates the immune system to secrete antibodies against the agent which is used to prepare vaccine. A vaccine is typically manufactured by using the disease-causing microorganism, which is weakened or killed to form a vaccine. Inactivated vaccine are type of vaccine, which are produced by growing the micro-organism (bacteria or viruses) on the culture medium, then inactivating them with heat and / or chemicals (formalin is mostly used for inactivation). Therefore, the components of the inactivated vaccine cannot replicate.

Browse Summary of the Research Report- https://www.coherentmarketinsights.com/market-insight/inactivated-polio-and-rabies-vaccines-market-3581

Moreover, the inactivated vaccine can be classified into two types such as whole killed vaccine and subunit vaccine. Moreover, when entire dose of inactivated vaccine is administered, the body elicits an immune response against the disease causing micro-organisms or viruses. Inactivated polio vaccine (IPV) and inactivated rabies vaccine (IRV) are most commonly used inactivated vaccine against polio and rabies, respectively, by global population.

Increasing U.S. Food and Drug Administration (U.S. FDA) approvals for inactivated vaccines and their launches (IPV and IRV) for public use are expected to drive the global inactivated polio and rabies vaccines market growth over the forecast period.

Manufacturers are indulged in research, launches, and approvals of inactivated vaccines in the global inactivated polio and rabies vaccines market. For instance, in June 2019, AJ Vaccines introduced adjuvant IPV vaccine in Denmark. It is different from already available IPV vaccines, as it provides enhanced immunization to the infants and children from polio due to the presence of adjuvant and lower doses of vaccine that is required for immunization. Moreover, some new vaccines against rabies received U.S. Food and Drug Administration (U.S. FDA) approvals. For instance, in October 2019, Sanofi Pasteur SA announced to receive the U.S. FDA approval of Imovax, and in 2018, GlaxoSmithKline Biologicals, announced to receive the U.S. FDA approval for RabAvert. Both the vaccines can be used for pre-exposure immunization and post-exposure treatment of rabies.Increasing incidences of rabies in the population is expected to spur the global inactivated polio and rabies vaccines market growth over the forecast period.

According to Center for Disease Control and Prevention, (CDC), 2019, in U.S., it has been reported that, other than dog, other animals are also responsible for spreading rabies in humans. For instance, according to the same source, in the U.S., during 2008-2017, 23 people were reported to be suffering from rabies, of which, eight people contracted rabies outside the U.S. The source of the rabies was checked and found that dog, bat, raccoon, and fox were found to be the carriers of rabies and rabies causes around 59,000 deaths world-wide every year. Despite of the availability of vaccine over 100 years, dog rabies have found to be common in the all regions with inadequate public health resources and having limited access to preventive treatment. Such regions also have few diagnostic facilities for life threatening diseases and surveillance of rabies occurrence among the animals is almost zero.Increasing awareness about polio among the population is expected to drive the global inactivated polio and rabies vaccines market growth over the forecast period.

According to WHO, 2018, world-wide incidences of polio have been decreased by 99%, since 1988 and only 22 cases of children suffering from polio were found in 2017. Moreover, only three countries such as Pakistan, Afghanistan, and Nigeria were not successful in eradicating polio from their countries. According to the same source, it has also been estimated that failure to eradicate polio, over the span of ten years, can result in 200,000 polio patients globally. Furthermore, active participation of government for increasing awareness among the population through social media platforms, newspapers, and announcements is expected to reduce number of polio cases world-wide.

Regional segmentation of the global inactivated polio and rabies vaccines market comprises North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America is expected to hold dominant position in the global inactivated polio and rabies vaccine market over the forecast period, owing to the increasing expenditure for maintaining rabies and polio free conditions in the region. Moreover, high income regions such as North America, Europe, and Latin America have eliminated cases of patients suffering from rabies and polio from their regions by increasing awareness among the population and conducting vaccination drives against rabies and polio, all over the region. High income regions incur very high expenditure, in order to maintain rabies and polio free environment and to survey any occurrence of the disease in the regions.

Moreover, according to the World Health Organization (WHO), 2019, low income regions such as Asia Pacific, Africa, and Latin America have reported highest number of deaths in the population because of rabies. For instance, according to the same source, per year around, 35,172 human deaths and 21,476 human deaths occur due to rabies in Asia Pacific and Africa respectively. The cases of patients suffering from polio in Asia Pacific are decreasing due to increasing awareness about the prevention of polio and rabies among the population and free immunization camps, which are organized by the government for immunizing the population against polio and rabies. Therefore, Asia Pacific is also expected to spur the global inactivated polio and rabies vaccines market growth over the forecast period.

The most important factor that can restrain the global inactivated vaccines market growth include safety of the vaccines. For instance, the inactivation process of the viruses may remain incomplete and the active virus may spread among the population causing the disease. Moreover, unavailability of the vaccines is another factor that is expected to hamper growth of the global inactivated vaccines market. For instance, in India, the polio drive, which was scheduled on 3rd February 2019, was postponed till 10th March 2019, due to unavailability of the polio vaccine.

Key Players

Some of the key players operating in the global inactivated vaccines market include Bharat Biotech., BIO-MED, Serum Institute of India Pvt. Ltd., Kedrion Biopharma Inc. GlaxoSmithKline plc. Bilthoven Biologicals, Merck & Co., Inc., and Pfizer Inc.

Request A Sample Copy - https://www.coherentmarketinsights.com/insight/request-sample/3581


About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]
*****************************************************************